Accelerating global expansion through the Bio-Challenger program hosted by the National Institute of Food and Drug Safety Evaluation
[by Ji, Yong Jun] CTX, a company specializing in advanced regenerative medicine and the development of treatments for rare diseases, announced on July 22 that the Charcot-Marie-Tooth (CMT) cell therapy development program of Cellatoz Therapeutics, a company it is set to acquire through an M&A, has been officially selected for the ‘2025 Bio-Challenger’ program organized by the National Institute of Food and Drug Safety Evaluation (NIFDS).
The ‘Bio-Challenger’ program is a government-supported initiative aimed at fostering the development of innovative advanced biopharmaceuticals that address unmet medical needs. Companies selected for the program receive various forms of support, including assignment of a dedicated consultant throughout the novel drug development process, preliminary review for potential designation as a fast-track candidate, and priority review assistance during the regulatory approval process.
바카라 배팅 법atoz Therapeutics is a company that successfully completed Phase 1 clinical trials for a 바카라 배팅 법 therapy targeting the rare disease CMT. The company is currently pursuing global technology transfer and preparing for Phase 2 clinical trials of the pipeline. Its selection for the Bio-Challenger program validates the competitiveness of its development pipeline and is expected to positively influence ongoing partnership negotiations with global pharmaceutical companies.
CTX, currently in the process of merging with Cellatoz Therapeutics, is a specialized R&D company focused on cell therapies. The company is developing treatments for Parkinson’s disease and natural killer (NK) cell therapies based on induced pluripotent stem cells (iPSC) technology. The company is led by Dr. Hwang Yu-kyeong, former director of the Cell Therapy Research Institute at GC Lab Cell.
“This selection holds significance not only in terms of R&D but also for global commercialization and investment attraction,” said Hwang Yu-kyeong, CEO of CTX. “We will expedite the completion of the merger and strive to establish ourselves as a leading CMT cell therapy company in the global rare disease market.”
Conversely, 바카라 배팅 법atoz Therapeutics is actively pursuing a global licensing-out strategy centered on Japan and the United States. Upon completion of the merger with CTX, the company plans to accelerate the development of its CMT pipeline.